Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Los Angeles-area Orthopedic Groups Become First in the Region to Offer the iovera° Treatment for Patients with Knee Pain
  • USA - English


News provided by

Myoscience

Jan 22, 2015, 03:00 ET

Share this article

Share toX

Share this article

Share toX


“In my practice I strive to offer my patients options that are the least invasive to their bodies and lives as possible,” said Luga Podesta, M.D., of the Podesta Orthopedic and Sports Medicine Institute.

Post this

Redwood City, CA (PRWEB) January 22, 2015 -- Myoscience announced today that Kerlan-Jobe Orthopaedic Clinic and Podesta Orthopedic and Sports Medicine Institute have joined a growing number of cutting-edge medical facilities in the nation, and are the first in the Los Angeles area, to offer the iovera° system for the treatment of anterior and interior knee pain. The iovera° system, cleared by the FDA to treat peripheral nerve pain, utilizes its patented Focused Cold TherapyTM delivery system to direct a controlled cold dosage via closed-end probes to specific nerves for precise, predictable, drug-free pain relief.

“We are pleased these practices have seen, first hand, the value of the iovera° system for their knee pain sufferers,” said Jeff Gold, myoscience CEO. “The iovera° system gives physicians and patients a unique option to address peripheral nerve pain in a very targeted, safe way harnessing the natural power of cold to temporarily stop nerves from signalling and to deliver immediate pain relief without systemic medication.”

Frequent knee pain limits function and mobility, and impairs quality of life for approximately 25% of adults.1 Peripheral nerves treated with the iovera° system are temporarily stopped from signalling for a period of time, followed by a restoration of function - results may vary per patient*. Because peripheral nerve function is disrupted rather than destroyed, the results are safe, effective and temporary.

“In my practice I strive to offer my patients options that are the least invasive to their bodies and lives as possible,” said Luga Podesta, M.D., of the Podesta Orthopedic and Sports Medicine Institute. “This procedure uses the simple power of cold in a very high-tech, precise way to essentially block specific nerve signals temporarily and deliver immediate pain relief.”

“The iovera° treatment has been a great addition to my clinical armamentarium for patients with knee pain. I can offer them highly targeted pain relief, and in many cases, help them avoid or reduce their need for systemic painkillers,” said Vernon Williams, M.D., of Kerlan Jobe Orthopaedic Clinic. “My patients are excited to have a natural, drug-free treatment that enables them to walk out of my office with reduced pain and stay that way for up to 3 months.”

The iovera° system delivers liquid nitrous oxide from a convenient and powerful handheld device to the closed-end probes of the Smart Tip during treatment. While this highly pressurized liquid travels from the handpiece to the Smart Tip, it undergoes a phase change becoming very cold, drawing in heat energy from the surrounding tissue and forming a precise zone of cold at the targeted nerve. The gaseous nitrous oxide returns into the handpiece, leaving nothing behind in the body. This precise cold treatment causes a reversible nerve block based on a process called Wallerian degeneration. Pain is relieved in sensory nerves, which send messages to the central nervous system. The nerve re-innervates 1-2 mm per day, which gives a predictable restoration of nerve function.

About iovera°
The Food and Drug Administration (FDA) cleared the iovera° system for use in peripheral nerves in January 2013. The iovera° system is being used most frequently for knee pain but can be used to treat pain in any peripheral nerve. The iovera° system is specifically cleared to destroy tissue during surgical procedures by applying cold temperature. It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. The iovera° system is not indicated for treatment of central nervous system tissue.

About the Kerlan-Jobe Orthopaedic Clinic
The Kerlan-Jobe Orthopaedic Clinic is a world leader in the diagnosis and treatment of orthopaedic and sports medicine injuries and illnesses. In addition to sports medicine, the clinic specializes in all aspects of orthopaedic care, including the diagnosis and treatment of the spine, shoulder, elbow, knee, hand and foot disorders, orthopaedic trauma, arthritis, congenital disorders, and work-related injuries. The clinic also conducts research in the areas of sports medicine and orthopaedic care. For more information about the Kerlan-Jobe Orthopaedic Clinic please visit: http://www.kerlanjobe.com. Patients interested in the iovera° treatment at Kerlan- Jobe can call: 310-665-7200.

About the Podesta Orthopedic and Sports Medicine Institute
Founded in 2008 by Dr. Luga Podesta in Thousand Oaks, CA, the staff of physicians, nurses, medical assistants, and radiological technicians is dedicated to delivering exemplary care to patients, while minimizing potential time lost from work or play. The Institute has expertise in the treatment of athletic and musculoskeletal injuries of the shoulder, elbow, knee and spine utilizing a sports medicine model to aggressively diagnose and treat all patients with orthopedic musculoskeletal injuries. When appropriate, the Podesta team strives to take a conservative, non- surgical approach to treatment. For more information about the Podesta Orthopedic and Sports Medicine Institute please visit: http://podestasportsmedicine.com. Patients interested in iovera° treatment at the Podesta Orthopedic and Sports Medicine Institute can call: 805-267-2902.

About myoscience
Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the ioverao system. The ioverao system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit http://www.myoscience.com.

© 2014 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience. MKT-0337 REV A

  • In a single arm, post-market study of knee pain, 70% of subjects reported an effect at ~2 months. 45% of subjects reported a continued effect at ~3 months.

1 Nguyen, Uyen-Sa D.T., DSc, et al. “Increasing Prevalence of Knee Pain and Symptomatic Knee Osteoarthritis,” Ann Intern Med. (2011 December 6); 155(11): 725–732.

Denise Keeler, Myoscience, +1 (650) 465-9709, [email protected]

Modal title

View PDF

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.